Publications

BibTex format

@article{Bonini:2020:10.1016/j.mpmed.2020.02.007,
author = {Bonini, M and Usmani, OS},
doi = {10.1016/j.mpmed.2020.02.007},
journal = {Medicine (United Kingdom)},
pages = {314--322},
title = {Drugs for airway disease},
url = {http://dx.doi.org/10.1016/j.mpmed.2020.02.007},
volume = {48},
year = {2020}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Asthma is a heterogeneous disease characterized by chronic airway inflammation and variable expiratory airflow limitation. It affects 5–15% of people worldwide and has shown an increasing prevalence over the last decade. The treatment of asthma is well established in current guidelines, with the aim of achieving optimal disease control and preventing acute exacerbations using a stepwise medication approach. Drugs are commonly divided into ‘relievers’, which quickly reverse airway obstruction, and ‘controllers’, which target the underlying inflammation providing long-term control. β2-adrenoceptor agonists are the most effective therapy for preventing and treating bronchial obstruction, while inhaled corticosteroids are recommended as first-line chronic therapy for persistent asthma. Drugs such as muscarinic antagonists, anti-leukotrienes and macrolides also play a role in disease management. New personalized therapies, such as biological agents or small molecules, have become available or are under development for treatment of severe asthma, together presenting opportunities with developments in biomarkers for interventions of precision medicine.
AU  - Bonini,M
AU  - Usmani,OS
DO  - 10.1016/j.mpmed.2020.02.007
EP  - 322
PY  - 2020///
SN  - 1357-3039
SP  - 314
TI  - Drugs for airway disease
T2  - Medicine (United Kingdom)
UR  - http://dx.doi.org/10.1016/j.mpmed.2020.02.007
VL  - 48
ER  -

Download

Professor Omar Usmani

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)